Table 2

Effect of MDR-reversing agents on sensitivity of LLC/CMV and LLC/cMOAT-1 cells to anticancer agents

TreatmentLLC/CMVLLC/cMOAT-1
IC50DMF2-aIC50DMF
μM μM
VCR0.029  ± 0.002 (1)2-b 0.234  ± 0.0182 (8.02)
 + CsA (10 μM)0.024  ± 0.003 (0.83)1.210.045  ± 0.004 (1.55)5.202-c
 + PAK-104P (5 μM)0.020  ± 0.002 (0.69)1.452-c 0.051  ± 0.007 (1.75)4.592-c
 + MK571 (5 μM)0.028  ± 0.003 (0.97)1.040.083  ± 0.003 (2.86)2.822-c
 + PSC833 (10 μM)0.022  ± 0.002 (0.76)1.322-c 0.098  ± 0.014 (3.38)2.392-c
 + BSO (10 μM)0.027  ± 0.004 (0.93)1.070.122  ± 0.015 (4.20)1.92-c
SN-380.065  ± 0.007 (1)0.408  ± 0.041 (6.28)
 + CsA (10 μM)0.060  ± 0.005 (0.92)1.080.088  ± 0.008 (1.35)4.62-c
 + PAK-104P (5 μM)0.058  ± 0.006 (0.90)1.110.096  ± 0.012 (1.48)4.252-c
 + MK571 (5 μM)0.066  ± 0.007 (1.02)0.980.153  ± 0.012 (2.35)2.672-c
 + PSC833 (10 μM)0.061  ± 0.007 (0.94)1.070.193  ± 0.024 (2.97)2.12-c
 + BSO (10 μM)0.051  ± 0.008 (0.88)1.140.158  ± 0.019 (2.43)2.582-c
Cisplatin2.576  ± 0.354 (1)7.820  ± 0.844 (3.04)
 + CsA (10 μM)2.464  ± 0.211 (0.96)1.053.060  ± 0.421 (1.19)2.562-c
 + PAK-104P (5 μM)2.412  ± 0.202 (0.94)1.073.211  ± 0.421 (1.25)2.442-c
 + MK571 (5 μM)2.520  ± 0.311 (0.98)1.023.989  ± 0.431 (1.55)1.962-c
 + PSC833 (10 μM)2.487  ± 0.233 (0.99)1.014.908  ± 0.601 (1.91)1.592-c
 + BSO (10 μM)2.101  ± 0.312 (0.82)1.233.616  ± 0.521 (1.40)2.162-c

To examine the effects of CsA, PSC833, MK571, PAK-104P or BSO on drug sensitivity, cells were preincubated with or without CsA, PSC833, MK571, or PAK-104P for 1 h or BSO for 24 h and then incubated with various concentrations of drugs. Data represent means of triplicate determinations (± S.E.) from at least three separate experiments.

    • ↵2-a DMF, dose-modifying factor (IC50 value of drug in cells was divided by IC50 value of drug combined with reversing agents).

    • ↵2-b Relative resistance (IC50 of drug for LLC/CMV with the reversing agents or LLC/cMOAT-1 with and without the reversing agents was divided by IC50 for LLC/CMV of drug without the reversing agents).

    • ↵2-c Values obtained for drug combined with the reversing agents, are significantly different from those obtained for drug alone (P < .05).